New Delhi News

Celiac Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Celiac Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 08
21:29 2023
Celiac Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously working towards developing 25+ Celiac Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Celiac Disease Overview

According to the World Gastroenterology Organization (WGO), Celiac disease also known as coeliac disease/non-tropical sprueor gluten-sensitive enteropathy, is defined as a chronic, multiple-organ small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. It is a serious autoimmune disorder where the ingestion of gluten leads to damage in the small intestine; it is not an allergy caused by gluten.

 

Celiac Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Celiac Disease Market.

 

The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Celiac Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Celiac Disease treatment therapies with a considerable amount of success over the years. Celiac Disease Key players such as – AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc.,  Amgen Inc., and others, are developing therapies for the Celiac Disease treatment 
  • Celiac Disease Emerging therapies such as – AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others are expected to have a significant impact on the Celiac Disease market in the coming years.   
  • In October 2022, Daprodustat received a mixed response from the Agency’s Cardiovascular and Renal Drugs Advisory Committee, however the committee tended to favour authorizing the medication solely for CKD patients with anaemia who are receiving dialysis

 

Route of Administration

Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Celiac Disease Pipeline Therapeutics Assessment

  • Celiac Disease Assessment by Product Type
  • Celiac Disease By Stage and Product Type
  • Celiac Disease Assessment by Route of Administration
  • Celiac Disease By Stage and Route of Administration
  • Celiac Disease Assessment by Molecule Type
  • Celiac Disease by Stage and Molecule Type

 

DelveInsight’s Celiac Disease Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Celiac Disease Therapeutics Market include:

Innovate Biopharmaceuticals, Teva Pharmaceutical Industries Ltd, ImmunogenX, LLC, Amgen, ChemoCentryx, Inc, Anokion SA, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, BioLineRx Ltd, and Takeda Pharmaceutical Company Limited, and others

 

Emerging Celiac Disease Drugs Under Different Phases of Clinical Development Include:

  • AMY02 : AMYRA Biotech AG
  • EQ102 : Equillium Bio.
  • DONQ52 : Chugai Pharmaceutical Co., Ltd.
  • CALY-002 : Calypso Biotech
  • Latiglutenase : ImmunogenX, Inc.
  • Ordesekimab : Amgen Inc.

 

Get a Free Sample PDF Report to know more about Celiac Disease Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight

 

Celiac Disease Pipeline Analysis:

The Celiac Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Celiac Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Celiac Disease Treatment.
  • Celiac Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Celiac Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Celiac Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Celiac Disease product details are provided in the report. Download the Celiac Disease pipeline report to learn more about the emerging Celiac Disease therapies

 

Celiac Disease Pipeline Market Drivers

  • Increasing prevalence of Celiac Disease
  • Increasing R&D activities
  • No Approved Therapy

 

Celiac Disease Pipeline Market Barriers

  • Limited patient awareness about the disease
  • Poor Patient Compliance

 

Scope of Celiac Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Celiac Disease Companies: AMYRA Biotech AG, Equillium Bio., Chugai Pharmaceutical Co., Ltd., Calypso Biotech, ImmunogenX, Inc.,  Amgen Inc., and others
  • Key Celiac Disease Therapies: AMY02, EQ102, DONQ52, CALY-002, Latiglutenase, Ordesekimab, and others
  • Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
  • Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 

 

Request for Sample PDF Report for Celiac Disease Pipeline Assessment and clinical trials

 

Table of Contents

1

Celiac Disease Report Introduction

2

Celiac Disease Executive Summary

3

Celiac Disease Overview

4

Celiac Disease- Analytical Perspective In-depth Commercial Assessment

5

Celiac Disease Pipeline Therapeutics

6

Celiac Disease Late Stage Products (Phase II/III)

7

Celiac Disease Mid Stage Products (Phase II)

8

Celiac Disease Early Stage Products (Phase I)

9

Celiac Disease Preclinical Stage Products

10

Celiac Disease Therapeutics Assessment

11

Celiac Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Celiac Disease Key Companies

14

Celiac Disease Key Products

15

Celiac Disease Unmet Needs

16 

Celiac Disease Market Drivers and Barriers

17

Celiac Disease Future Perspectives and Conclusion

18

Celiac Disease Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Celiac Disease drugs and therapies 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Related Articles